SIIC MEDTECH<08018> - Results Announcement
SIIC Medical Science and Technology (Group) Limited announced on 29/07/2003:
(stock code: 08018 )
Year end date: 31/12/2003
Currency: HKD
Auditors' Report: N/A
Review of Interim Report by: Both Audit Committee and Auditors
Important Note:
This result announcement form only contain extracted information
from and should be read in conjunction with the detailed results
announcement of the issuer, which can be view on the GEM website
at http://www.hkgem.com
(Unaudited )
(Unaudited ) Last
Current Corresponding
Period Period
from 01/01/2003 from 01/01/2002
to 30/06/2003 to 30/06/2002
Note ('000 ) ('000 )
Turnover 2 : 567,440 419,884
Profit/(Loss) from Operations : 98,544 88,462
Finance cost : (149) 0
Share of Profit/(Loss) of
Associates : 18,780 16,208
Share of Profit/(Loss) of
Jointly Controlled Entities : 470 (5)
Profit/(Loss) after Tax & MI : 50,355 45,518
% Change over Last Period : +10.6 %
EPS/(LPS)-Basic (in dollars) 3 : 0.0812 0.0734
-Diluted (in dollars) 3 : 0.0812 0.0729
Extraordinary (ETD) Gain/(Loss) : 0 0
Profit/(Loss) after ETD Items : 50,355 45,518
2nd Quarterly Dividend : N/A N/A
per Share
(Specify if with other : N/A N/A
options)
B/C Dates for
2nd Quarterly Dividend : N/A
Payable Date : N/A
B/C Dates for (-)
General Meeting : N/A
Other Distribution for : N/A
Current Period
B/C Dates for Other
Distribution : N/A
For and on behalf of
SIIC Medical Science and Technology (Group) Limited
Name : Wong Mei Ling, Marina
Title : Company Secretary
Responsibility statement
The directors of the Company (the "Directors") as at the date hereof
hereby collectively and individually accept full responsibility for
the accuracy of the information contained in this results announcement
form (the "Information") and confirm, having made all reasonable
inquiries, that to the best of their knowledge and belief the
Information are accurate and complete in all material respects and
not misleading and that there are no other matters the omission of
which would make the Information herein inaccurate or misleading. The
Directors acknowledge that the Stock Exchange has no responsibility
whatsever with regard to the Information and undertake to indemnify
the Exchange against all liability incurred and all losses suffered
by the Exchange in connection with or relating to the Information.
Remarks:
1. Basis of preparation
The principal accounting policies adopted in preparing the unaudited
consolidated financial statements of the Group conform with
accounting principles generally accepted in Hong Kong and accounting
standards issued by the Hong Kong Society of Accountants. The
consolidated financial statements have been prepared under the
historical cost convention as modified for revaluation of certain
properties and investments in securities.
2. Turnover
Turnover represents the net amounts received and receivable for
goods sold by the Group to outside customers during the period.
For the period ended 30th June 2003 and 2002, the Group was engaged
in the manufacture and sale of Chinese medicine and health
supplement products. More than 90% of the Group's turnover,
contribution to operating profit and assets was attributable to this
business segment and located in the PRC.
3. Earnings per share
The calculation of the basic and diluted earnings per share for the
period is based on the following data:
For the six months ended 30th June
2003 2002
Earnings:
Net profit for the period and
earnings for the purpose of
basic and diluted earnings
per share HK$50,355,000 HK$45,518,000
============= =============
Number of shares :
Weighted average number of
ordinary shares for the
purpose of basic earnings
per share 620,005,470 620,000,000
Effect of dilutive potential
ordinary shares
- share options 122,943 4,071,419
----------- -----------
Weighted average number of
ordinary shares for the
purpose of diluted earnings
per share 620,128,413 624,071,419
=========== ===========
4. Change of figures reported for the last corresponding period
To conform with current year's presentation of financal statements,
the comparative figure for profit from operations was increased by
HK$245,000 as the amortisation of goodwill on jointly controlled
entities was not included in administrative expenses.
|